✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Evacetrapib is an investigational drug.
There have been 22 clinical trials for Evacetrapib. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2014.
The most common disease conditions in clinical trials are Cardiovascular Diseases, Hypercholesterolemia, and Dyslipidemias. The leading clinical trial sponsors are Eli Lilly and Company, The Cleveland Clinic, and [disabled in preview].
There are ninety-one US patents protecting this investigational drug and seven hundred and forty-six international patents.
Recent Clinical Trials for Evacetrapib
|A Study of Different Particle Sizes of Evacetrapib in Healthy Participants||Eli Lilly and Company||Phase 1|
|A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia||Eli Lilly and Company||Phase 3|
|A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants||Eli Lilly and Company||Phase 1|
Top disease conditions for Evacetrapib
Top clinical trial sponsors for Evacetrapib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Evacetrapib||See Plans and Pricing||Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein||Merck Sharp & Dohme Corp. (Rahway, NJ)||See Plans and Pricing|
|Evacetrapib||See Plans and Pricing||Soluble guanylate cyclase stimulators||Merck Sharp & Dohme Corp. (Rahway, NJ)||See Plans and Pricing|
|Evacetrapib||See Plans and Pricing||Antidiabetic compounds||Merck Sharp & Dohme Corp. (Rahway, NJ)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Evacetrapib||European Patent Office||EP3174537||2034-07-29||See Plans and Pricing|
|Evacetrapib||World Intellectual Property Organization (WIPO)||WO2016018729||2034-07-29||See Plans and Pricing|
|Evacetrapib||Argentina||AR107154||2035-12-22||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|